Drug Trial Radar · NCT04096326
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
Last checked: Nov 20, 2026Latest source record: Jul 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
198
Actual
Start
Sep 26, 2019
Primary completion
Sep 9, 2020
Study completion Sep 9, 2020
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).
Conditions
- Glabellar Lines
Interventions
AGN-151586Drug
AGN-151586 solution for injection.
PlaceboDrug
Placebo solution for injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7Time frame: Baseline (Day 1) through Day 7
- Number of Participants Who Experience One or More Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug until the end of study (up to 42 days)
- Number of Participants With Potentially Clinically Significant Laboratory Parameters Post InterventionTime frame: From first dose of study drug until the end of study (up to 42 days)
- Number of Participants With Potentially Clinically Significant Vital Signs Post InterventionTime frame: From first dose of study drug until the end of study (up to 42 days)
- Number of Participants With Potentially Clinically Significant Electrocardiogram Findings Post InterventionTime frame: From first dose of study drug until the end of study (up to 42 days)
- Number of Participants With Anti-drug Antibodies (ADAs)Time frame: Up to Day 42
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Center for Dermatology Clinical Research /ID# 237798
Fremont, California
Ava T. Shamban MD - Santa Monica. /ID# 235353
Santa Monica, California
Skin and Cancer Associates, LLP /ID# 236231
Miami, Florida
Laser and Skin Surgery Center of Indiana /ID# 236588
Indianapolis, Indiana
Wilmington Dermatology Center /ID# 237055
Wilmington, North Carolina
Kgl, Llc /Id# 234798
Newtown Square, Pennsylvania
DermResearch Inc. /ID# 234483
Austin, Texas
Austin Institute for Clinical Research at SBA Dermatology /ID# 236646
Houston, Texas
Austin Institute for Clinical Research /ID# 237135
Pflugerville, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.